Literature DB >> 20538322

Downregulation of HNF-1B in renal cell carcinoma is associated with tumor progression and poor prognosis.

Alexander Buchner1, Mirna Castro, Anja Hennig, Tanja Popp, Gerald Assmann, Christian G Stief, Wolfgang Zimmermann.   

Abstract

OBJECTIVES: The aim of this study was to identify new prognostic factors in metastatic renal cell carcinoma (RCC) based on the analysis of precisely defined metastatic tissue.
METHODS: Expression profiling was done on 26 snap-frozen samples of clear-cell RCC metastases with complete follow-up (up to 116 months) using laser microdissection and oligonucleotide microarrays (Affymetrix). A prognosis-associated gene signature was determined using the semi-supervised principal components analysis method. Validation was performed with quantitative RT-PCR on samples of normal renal tissue (n = 6), RCC primary tumor (n = 57), and RCC metastases (n = 59). Immunohistochemistry (IHC) was done to localize HNF-1B.
RESULTS: Analysis of expression data revealed a three-gene signature consisting of HNF-1B, KIAA1919, and SYDE1, which discriminated well between 2 prognosis groups (P < .05), independently of the TNMG classification. Expression of HNF-1B was analyzed in detail. HNF-1B mRNA expression correlated with malignant transformation and progression (normal renal tissue > primary tumor > metastasis; P < .0001). There was a significant correlation between high HNF-1B mRNA expression in primary tumor and better prognosis (P < .05). IHC showed a specific nuclear HNF-1B staining confined to the tumor cells of the primary tumors and of the metastases.
CONCLUSIONS: The level of HNF-1B mRNA expression significantly decreases with tumor progression, and patients with high HNF-1B mRNA levels have a significantly better prognosis. HNF-1B might be a useful prognostic factor for metastatic RCC and also a potential therapeutic target in the future. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538322     DOI: 10.1016/j.urology.2010.03.042

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  19 in total

1.  Large-scale fine mapping of the HNF1B locus and prostate cancer risk.

Authors:  Sonja I Berndt; Joshua Sampson; Meredith Yeager; Kevin B Jacobs; Zhaoming Wang; Amy Hutchinson; Charles Chung; Nick Orr; Sholom Wacholder; Nilanjan Chatterjee; Kai Yu; Peter Kraft; Heather Spencer Feigelson; Michael J Thun; W Ryan Diver; Demetrius Albanes; Jarmo Virtamo; Stephanie Weinstein; Fredrick R Schumacher; Geraldine Cancel-Tassin; Olivier Cussenot; Antoine Valeri; Gerald L Andriole; E David Crawford; Christopher Haiman; Brian Henderson; Laurence Kolonel; Loic Le Marchand; Afshan Siddiq; Elio Riboli; Ruth C Travis; Rudolf Kaaks; William Isaacs; Sarah Isaacs; Kathleen E Wiley; Henrik Gronberg; Fredrik Wiklund; Pär Stattin; Jianfeng Xu; S Lilly Zheng; Jielin Sun; Lars J Vatten; Kristian Hveem; Inger Njølstad; Daniela S Gerhard; Margaret Tucker; Richard B Hayes; Robert N Hoover; Joseph F Fraumeni; David J Hunter; Gilles Thomas; Stephen J Chanock
Journal:  Hum Mol Genet       Date:  2011-05-16       Impact factor: 6.150

2.  HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas.

Authors:  Mianen Sun; Pan Tong; Wen Kong; Baijun Dong; Yiran Huang; In Young Park; Lijun Zhou; Xian-De Liu; Zhiyong Ding; Xuesong Zhang; Shanshan Bai; Peter German; Reid Powell; Quan Wang; Xuefei Tong; Nizar M Tannir; Surena F Matin; W Kimryn Rathmell; Gregory N Fuller; Ian E McCutcheon; Cheryl L Walker; Jing Wang; Eric Jonasch
Journal:  Cancer Res       Date:  2017-08-14       Impact factor: 12.701

3.  Expression, Epigenetic and Genetic Changes of HNF1B in Endometrial Lesions.

Authors:  Kristýna Němejcová; Ivana Tichá; Petra Kleiblová; Michaela Bártů; David Cibula; Kateřina Jirsová; Pavel Dundr
Journal:  Pathol Oncol Res       Date:  2015-12-19       Impact factor: 3.201

4.  Expression of bile duct transcription factor HNF1β predicts early tumor recurrence and is a stage-independent prognostic factor in hepatocellular carcinoma.

Authors:  Ray-Hwang Yuan; Hong-Shiee Lai; Hey-Chi Hsu; Po-Lin Lai; Yung-Ming Jeng
Journal:  J Gastrointest Surg       Date:  2014-07-23       Impact factor: 3.452

Review 5.  Polycystic kidney features of the renal pathology in glycogen storage disease type I: possible evolution to renal neoplasia.

Authors:  Monika Gjorgjieva; Laure Monteillet; Julien Calderaro; Gilles Mithieux; Fabienne Rajas
Journal:  J Inherit Metab Dis       Date:  2018-06-04       Impact factor: 4.982

6.  Insights into the etiology and physiopathology of MODY5/HNF1B pancreatic phenotype with a mouse model of the human disease.

Authors:  Evans Quilichini; Mélanie Fabre; Christoffer Nord; Thassadite Dirami; Axelle Le Marec; Silvia Cereghini; Raymond C Pasek; Maureen Gannon; Ulf Ahlgren; Cécile Haumaitre
Journal:  J Pathol       Date:  2021-03-18       Impact factor: 7.996

7.  Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma.

Authors:  Song Wu; Yong Wang; Liang Sun; Zhiling Zhang; Zhimao Jiang; Zike Qin; Hui Han; Zhuowei Liu; Xianxin Li; Aifa Tang; Yaoting Gui; Zhiming Cai; Fangjian Zhou
Journal:  BMC Cancer       Date:  2011-09-26       Impact factor: 4.430

8.  Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk.

Authors:  Jodie N Painter; Tracy A O'Mara; Jyotsna Batra; Timothy Cheng; Felicity A Lose; Joe Dennis; Kyriaki Michailidou; Jonathan P Tyrer; Shahana Ahmed; Kaltin Ferguson; Catherine S Healey; Susanne Kaufmann; Kristine M Hillman; Carina Walpole; Leire Moya; Pamela Pollock; Angela Jones; Kimberley Howarth; Lynn Martin; Maggie Gorman; Shirley Hodgson; Ma Magdalena Echeverry De Polanco; Monica Sans; Angel Carracedo; Sergi Castellvi-Bel; Augusto Rojas-Martinez; Erika Santos; Manuel R Teixeira; Luis Carvajal-Carmona; Xiao-Ou Shu; Jirong Long; Wei Zheng; Yong-Bing Xiang; Grant W Montgomery; Penelope M Webb; Rodney J Scott; Mark McEvoy; John Attia; Elizabeth Holliday; Nicholas G Martin; Dale R Nyholt; Anjali K Henders; Peter A Fasching; Alexander Hein; Matthias W Beckmann; Stefan P Renner; Thilo Dörk; Peter Hillemanns; Matthias Dürst; Ingo Runnebaum; Diether Lambrechts; Lieve Coenegrachts; Stefanie Schrauwen; Frederic Amant; Boris Winterhoff; Sean C Dowdy; Ellen L Goode; Attila Teoman; Helga B Salvesen; Jone Trovik; Tormund S Njolstad; Henrica M J Werner; Katie Ashton; Tony Proietto; Geoffrey Otton; Gerasimos Tzortzatos; Miriam Mints; Emma Tham; Per Hall; Kamila Czene; Jianjun Liu; Jingmei Li; John L Hopper; Melissa C Southey; Arif B Ekici; Matthias Ruebner; Nicola Johnson; Julian Peto; Barbara Burwinkel; Frederik Marme; Hermann Brenner; Aida K Dieffenbach; Alfons Meindl; Hiltrud Brauch; Annika Lindblom; Jeroen Depreeuw; Matthieu Moisse; Jenny Chang-Claude; Anja Rudolph; Fergus J Couch; Janet E Olson; Graham G Giles; Fiona Bruinsma; Julie M Cunningham; Brooke L Fridley; Anne-Lise Børresen-Dale; Vessela N Kristensen; Angela Cox; Anthony J Swerdlow; Nicholas Orr; Manjeet K Bolla; Qin Wang; Rachel Palmieri Weber; Zhihua Chen; Mitul Shah; Juliet D French; Paul D P Pharoah; Alison M Dunning; Ian Tomlinson; Douglas F Easton; Stacey L Edwards; Deborah J Thompson; Amanda B Spurdle
Journal:  Hum Mol Genet       Date:  2014-11-06       Impact factor: 6.150

9.  Expression of HNF-1β in cervical carcinomas: an immunohistochemical study of 155 cases.

Authors:  Kristýna Němejcová; David Cibula; Pavel Dundr
Journal:  Diagn Pathol       Date:  2015-03-25       Impact factor: 2.644

10.  Functional relevance of a six mesenchymal gene signature in epithelial-mesenchymal transition (EMT) reversal by the triple angiokinase inhibitor, nintedanib (BIBF1120).

Authors:  Ruby Yun-Ju Huang; Kuee Theng Kuay; Tuan Zea Tan; Mohammad Asad; Hei Mui Tang; Aloysius Hsien Chun Ng; Jieru Ye; Vin Yee Chung; Jean Paul Thiery
Journal:  Oncotarget       Date:  2015-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.